Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2011 Dec 15;17(24):7508-10.
doi: 10.1158/1078-0432.CCR-11-2556. Epub 2011 Nov 7.

BEAMing sheds light on drug resistance

Josh Lauring  1 , Ben Ho Park
Affiliations
Comment

BEAMing sheds light on drug resistance

Josh Lauring et al. Clin Cancer Res. .

Abstract

Targeted therapies against somatically altered genes are currently used for the treatment of many human cancers. The nascent technology known as BEAMing has the potential to increase the clinical utility of these agents because it allows for the detection of cancer mutations in peripheral blood, providing a rapid assessment of tumor mutation status.

PubMed Disclaimer

Figures

Figure 1
Figure 1. Principles of BEAMing
Shown are the sequential steps involved with BEAMing. Results are expressed as a ratio of mutant to wild type DNA molecules using flow cytometry providing a quantitative measurement of mutant DNA present in the plasma. Figure adapted with permission from Inostics.
See this image and copyright information in PMC

Comment on

References

    1. Taniguchi K, Uchida J, Nishino K, et al. Quantitative detection of EGFR mutations in circulating tumor DNA derived from lung adenocarcinomas. Clin Cancer Res. 2011 - PubMed
    1. Dressman D, Yan H, Traverso G, Kinzler KW, Vogelstein B. Transforming single DNA molecules into fluorescent magnetic particles for detection and enumeration of genetic variations. Proc Natl Acad Sci U S A. 2003;100:8817–22. - PMC - PubMed
    1. Diehl F, Li M, He Y, Kinzler KW, Vogelstein B, Dressman D. BEAMing: single-molecule PCR on microparticles in water-in-oil emulsions. Nat Methods. 2006;3:551–9. - PubMed
    1. Kobayashi S, Boggon TJ, Dayaram T, et al. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005;352:786–92. - PubMed
    1. Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med. 2005;2:e73. - PMC - PubMed